Prostate International最新文献

{"title":"Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland","authors":"Jian Pan,&nbsp;Dingwei Ye,&nbsp;Yao Zhu","doi":"10.1016/j.prnil.2022.04.005","DOIUrl":"10.1016/j.prnil.2022.04.005","url":null,"abstract":"<div><h3>Background</h3><p>Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved for use in breast cancer susceptibility gene (BRCA)-mutated metastatic castration-resistant prostate cancer (mCPRC) patients. Our aim was to evaluate the adverse events (AEs) and efficacy of Olaparib in the treatment of mCRPC patients from the Chinese mainland.</p></div><div><h3>Methods</h3><p>We retrospectively included mCPRC patients treated with Olaparib more than for 28 days. Patients with alterations in 15 homologous recombination repair (HRR) genes were defined as the HRRmt group, and the rest were defined as the HRRwt group. The efficacy was analyzed by prostate-specific antigen (PSA) decreased rate and PSA progression-free survival (PFS). The partial response, good response, and high response of PSA were defined as a reduction of between 0% and 50%, greater than 50%, and greater than 90% from baseline.</p></div><div><h3>Results</h3><p>A total of 43 patients were enrolled in this study, including 26 HRRmt group patients and 17 HRRwt group patients. Two HRRwt patients received additional abiraterone therapy. A partial response, good response, and high response were achieved in 89% (23/26), 59% (15/26), and 15% (4/26) of HRRmt group patients, respectively. In HRRwt group, 59% (10/17), 35% (6/17), and 12% (2/17) of patients met the criteria of partial response, good response, and high response, respectively. Median PFS was 8.0 months in the HRRmt group and 3.0s months in the HRRwt group (HR, 0.61; 95% CI, 0.24–1.14; <em>p</em> = 0.148), respectively. All the 20 patients had AEs during Olaparib treatment. Ten episodes of grade 3 or 4 AEs were observed in four patients. The most common all-grade AEs were fatigue or asthenia (70%), anemia (65%), and decreased appetite (55%).</p></div><div><h3>Conclusions</h3><p>Most of the AEs were tolerated, and Olaparib was effective in mCRPC patients with HRR deficiency. In addition, the underlying mechanism of the efficacy of Olaparib observed in HRRwt group patients remained explored.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 3","pages":"Pages 142-147"},"PeriodicalIF":3.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/a2/main.PMC9520412.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review","authors":"Sachin Perera ,&nbsp;Jodie McDonald ,&nbsp;Isabella Williams ,&nbsp;Jonathan O'Brien ,&nbsp;Declan Murphy ,&nbsp;Nathan Lawrentschuk","doi":"10.1016/j.prnil.2022.08.002","DOIUrl":"10.1016/j.prnil.2022.08.002","url":null,"abstract":"<div><p>Low-risk prostate cancer has traditionally seen a preference towards avoiding treatment-related harms with active surveillance (AS) and multimodal monitoring protocols utilized to assess for disease progression. Large trials have shown variations in mortality and cancer survival benefit between AS and radical treatment, which has prompted further trials into the management of low-risk disease. Nonradical treatments for men on AS have been an emerging field and yet to enter mainstream guidelines or practice. These include pharmacological treatments, focal therapy, nutraceuticals, immunotherapy, and exercise. We present a review of all current major randomized clinical trials for nonradical treatment of men on AS and summarize their findings.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 3","pages":"Pages 117-122"},"PeriodicalIF":3.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/91/main.PMC9520502.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simplified Chinese version of the international prostate symptom score and the benign prostatic hyperplasia impact index: cross-cultural adaptation, reliability, and validity for patients with benign prostatic hyperplasia","authors":"Rong-liang Dun ,&nbsp;Jian-min Mao ,&nbsp;Chao Yu ,&nbsp;Qiang Zhang ,&nbsp;Xiao-hua Hu ,&nbsp;Wen-jing Zhu ,&nbsp;Guang-chong Qi ,&nbsp;Yu Peng","doi":"10.1016/j.prnil.2022.04.001","DOIUrl":"10.1016/j.prnil.2022.04.001","url":null,"abstract":"<div><h3>Background</h3><p>The aim of this study was to translate and cross-culturally adapt the international prostate symptom score (IPSS) and benign prostatic hyperplasia impact index (BII) into simplified Chinese for mainland Chinese patients with benign prostatic hyperplasia (BPH).</p></div><div><h3>Methods</h3><p>The original English IPSS and BII were translated into simplified Chinese versions based on cross-cultural adaptation guidelines. Internal consistency was evaluated with Cronbach’s α, then test-retest reliability with intraclass correlation coefficients (ICCs) in stable patients. The validity of these two adaptations was tested by the correlation between the IPSS and BII with visual prostate symptom score (VPSS) and 36 items Short Form Health Survey (SF-36). The floor and ceiling effects were calculated by the proportion of participants who obtained the highest and lowest possible score.</p></div><div><h3>Results</h3><p>A total of 105 native Chinese-speaking patients with BPH were enrolled. Cronbach’s α was over 0.75 for the simplified Chinese IPSS (IPSS 0.815; IPSS-symptom 0.782) and 0.709 for the simplified Chinese BII, indicating acceptable internal consistency. The ICCs for the test-retest reliability were over 0.75 (IPSS, <em>r</em> = 0.836; IPSS-symptom, <em>r</em> = 0.801; IPSS-quality of life, <em>r</em> = 0.794; BII, <em>r</em> = 0.758), indicating excellent test-retest reliability. There were very good positive correlations between IPSS and BII (<em>r</em> = 0.605), as well as VPSS (<em>r</em> = 0.634), and very good or good negative correlations between IPSS-Qol and SF-36 physical functioning (<em>r</em> = −0.621), and vitality (<em>r</em> = −0.659), and between BII and SF-36 physical functioning (<em>r</em> = −0.421). No floor or ceiling effect was detected in the simplified Chinese IPSS and BII.</p></div><div><h3>Conclusions</h3><p>This study indicates that the simplified Chinese IPSS and BII are reliable and valid measurements of the symptom and quality of life among Chinese patients with BPH, which is likely to be widely used in this population.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 3","pages":"Pages 162-168"},"PeriodicalIF":3.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/4d/main.PMC9520413.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic-assisted simple prostatectomy versus holmium laser enucleation of the prostate for large benign prostatic hyperplasia: A single-center preliminary study in Korea","authors":"Byung Hoon Kim,&nbsp;Hye Jin Byun","doi":"10.1016/j.prnil.2022.05.004","DOIUrl":"10.1016/j.prnil.2022.05.004","url":null,"abstract":"<div><h3>Background</h3><p>Holmium laser enucleation of the prostate (HoLEP) and robotic-assisted simple prostatectomy (RASP) are the two most important therapeutic modalities for large benign prostatic hyperplasia. However, there are currently no studies comparing these two treatments in a Korean setting. In this study, the authors seek to compare the safety and efficacy associated with these procedures.</p></div><div><h3>Methods</h3><p>The authors retrospectively analyzed 59 male patients who underwent HoLEP (n = 26) or RASP (n = 33) at single center. The following preoperative data were compared: age, the International Prostatic Symptom Score (IPSS), transrectal ultrasonography, uroflowmetry, and hemoglobin. Intraoperative data included operation time and specimen weight. Postoperative data included change in IPSS, uroflowmetry, and hemoglobin. Length of stay, catheterization time, and complications were also reviewed.</p></div><div><h3>Results</h3><p>No significant differences between the two groups were found in terms of age, total prostate, and transitional volume. Postoperatively, both groups showed similar improvement in the maximum flow rate, post-void residual urine, IPSS, and quality of life. Intraoperatively, there were no differences regarding operation time and resected prostate volume. Catheter removal time and length of stay were significantly shorter in the HoLEP group than the RASP group. In addition, postoperative hemoglobin changes were significantly lower in the HoLEP group. However, incontinence rates at 1 month and 2 months postoperative in the RASP group were lower than the HoLEP group.</p></div><div><h3>Conclusions</h3><p>Both HoLEP and RASP can produce excellent postoperative outcomes. However, catheter removal time, length of stay, and hemoglobin changes were more favorable in the HoLEP group. On the other hand, postoperative incontinence was more favorable in the RASP group. These factors must be heavily considered when deciding surgical the method for large benign prostatic hyperplasia.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 3","pages":"Pages 123-128"},"PeriodicalIF":3.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/53/main.PMC9520426.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer","authors":"Jung Kwon Kim ,&nbsp;Yoo Sung Song ,&nbsp;Won Woo Lee ,&nbsp;Hak Jong Lee ,&nbsp;Sung Il Hwang ,&nbsp;Sung Kyu Hong","doi":"10.1016/j.prnil.2022.04.003","DOIUrl":"10.1016/j.prnil.2022.04.003","url":null,"abstract":"<div><h3>Background</h3><p>Positron emission tomography (PET) using different positron-emitting radiopharmaceuticals has emerged as a promising new metabolic diagnostic tool for the evaluation of a variety of malignant diseases. Thus, we investigated the diagnostic efficacy of F-18-Fluorocholine positron emission tomography/computed tomography (PET/CT) and multiparametric magnetic resonance imaging (mpMRI) for the detection and localization of tumors within the prostate with the correlating histopathology as the standard of reference.</p></div><div><h3>Methods</h3><p>Forty patients with histologically proven prostate cancer underwent both F-18-Fluorocholine PET/CT and mpMRI before robot-assisted laparoscopic radical prostatectomy (RARP). The maximum standard uptake values and the tumor-to-background ratio were measured on a sextant basis. In brief, the sextants were defined as right apex, right middle, right base, left apex, left middle, and left base. For each tumor region, the correlation of the tumor localization based on the sextant in both F-18-Fluorocholine PET/CT and mpMRI scans with the histopathological results was determined.</p></div><div><h3>Results</h3><p>The correlation between both imaging modalities and RARP pathology representing (1) all cancer and (2) clinically significant cancer defined as a ≥ International Society of Urological Pathology grade of 2 showed that the sensitivity and the area under the curve (AUC) were higher for mpMRI than for F-18-Fluorocholine PET/CT. In contrast, F-18-Fluorocholine PET/CT had relatively higher specificity than mpMRI. Importantly, we found a very high AUC value of over 0.8 in both imaging modalities.</p></div><div><h3>Conclusion</h3><p>mpMRI had results superior to F-18-Fluorocholine PET/CT in assessing intraprostatic tumor localization. However, F-18-Fluorocholine PET/CT showed superiority in terms of specificity. Thus, using both modalities in conjunction could provide better treatment planning.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 3","pages":"Pages 152-157"},"PeriodicalIF":3.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1a/55/main.PMC9520420.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33501923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic-assisted simple prostatectomy after prostatic arterial embolization for large benign prostate hyperplasia: Initial experience","authors":"Sung-Chul Kam ,&nbsp;Jung-Won Park ,&nbsp;Myung-Ki Kim ,&nbsp;Kun-Yung Kim ,&nbsp;Ki-Soo Lee ,&nbsp;Tae-Hyo Kim ,&nbsp;Yu-Seob Shin","doi":"10.1016/j.prnil.2022.04.004","DOIUrl":"10.1016/j.prnil.2022.04.004","url":null,"abstract":"<div><h3>Background and objective</h3><p>We aimed to evaluate the safety and efficacy of robot-assisted simple prostatectomy (RASP) after prostatic arterial embolization (PAE) in large benign prostatic hyperplasia (BPH).</p></div><div><h3>Material and methods</h3><p>This retrospective study included 11 cases of PAE and subsequent RASP, performed on 11 patients with BPH from March 2018 to September 2020. Clinical information on the patients was collected before surgery and 3 months after surgery. For the quantification of lower urinary tract symptoms (LUTS), International Prostate Symptom Scores (IPSSs), prostate-specific antigen (PSA) levels, urinary peak flow rate (Qmax), voided volume (Vvol), and postvoid residual volume (PVR) were measured.</p></div><div><h3>Results</h3><p>PAE and the subsequent RASP were successfully performed in all 11 patients. The mean total prostate volume was 129.7 ± 65.1 mL, and the transitional zone volume was 71.7 ± 5.9 mL. The mean resected prostate volume was 60.8 ± 26.1 mL. The mean hemoglobin level of the patients prior to PAE was 14.2 ± 2.3 g/dL, and one day after RASP, the hemoglobin level was 12.4 ± 1.9 g/dL. The outcome indicated that there was a considerable decline in IPSS and PVR after RASP was performed compared to before PAE (21.6 ± 9.4 vs. 10.6 ± 8.0 and 159.4 ± 145.8 mL vs. 43.9 ± 45.9 mL). Qmax and Vvol significantly improved after RASP was performed (7.6 ± 5.2 mL/s vs. 26.1 ± 12.6 mL/s; 114.2 ± 92.5 mL vs. 192.4 ± 91.8 mL, respectively).</p></div><div><h3>Conclusion</h3><p>This research demonstrated that RASP could be performed safely and effectively after PAE in patients with large BPH.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 3","pages":"Pages 148-151"},"PeriodicalIF":3.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/64/main.PMC9520415.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33503435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between predictors of progression of benign prostatic hyperplasia and moderate-to-severe prostatitis-like symptoms: A propensity score–matched analysis","authors":"Jun Ho Lee ,&nbsp;Yeon Won Park ,&nbsp;Sin Woo Lee ,&nbsp;Jae Duck Choi ,&nbsp;Jung Yoon Kang ,&nbsp;Tag Keun Yoo","doi":"10.1016/j.prnil.2022.03.002","DOIUrl":"10.1016/j.prnil.2022.03.002","url":null,"abstract":"<div><h3>Background</h3><p>We investigated the association between moderate-to-severe prostatitis-like symptoms and the predictors of benign prostatic hyperplasia (BPH) progression.</p></div><div><h3>Methods</h3><p>Men who underwent health checkups were analyzed. We classified symptoms as “moderate to severe” if the pain score according to the National Institutes of Health-Chronic Prostatitis Symptoms Index was ≥8 and predictors of the progression of BPH were defined as having a prostate-specific antigen (PSA) ≥1.6 ng/mL, total prostate volume (TPV) ≥31 mL, international prostate symptom score (IPSS) ≥20, and maximal flow rate (Q_max) &lt;10.6 mL/s. A total of 8368 patients formed the cohort for propensity score matching, including 445 men with moderate-to-severe prostatitis-like symptoms and 5390 men with no symptoms; ultimately, however, the propensity score of these groups matched at a 1:2 ratio.</p></div><div><h3>Results</h3><p>After propensity matching, the two groups were evenly distributed with respect to age, International Index of Erectile Function-5 score, metabolic syndrome, and testosterone. The percentage of participants with ≥1 predictor for the progression of BPH, a TPV of ≥31 cm³, PSA levels of ≥1.6 ng/mL, Q_max &lt;10.6 mL/s, and IPSS ≥20 were all greater in men with moderate-to-severe prostatitis-like symptoms. There were significant differences in the percentage of participants with ≥1 predictor for the progression of BPH (30.6% vs. 58.0%; p &lt; 0.001), Q_max &lt;10.6 mL/s (3.9% vs. 7.0%, p = 0.023), and IPSS ≥20 (9.6% vs. 44.7%, p &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>Moderate-to-severe prostatitis-like symptoms are significantly and independently associated with predictors of BPH progression.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 2","pages":"Pages 92-95"},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888222000150/pdfft?md5=0d9f6582266fd46e4cbb8d0b84f29d1d&pid=1-s2.0-S2287888222000150-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48450970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate diseases and microbiome in the prostate, gut, and urine","authors":"Makito Miyake ,&nbsp;Yoshihiro Tatsumi ,&nbsp;Kenta Ohnishi ,&nbsp;Tomomi Fujii ,&nbsp;Yasushi Nakai ,&nbsp;Nobumichi Tanaka ,&nbsp;Kiyohide Fujimoto","doi":"10.1016/j.prnil.2022.03.004","DOIUrl":"10.1016/j.prnil.2022.03.004","url":null,"abstract":"<div><p>The microbiome in various organs involves a vast network that plays a key role in the health and wellness of the human body. With recent advances in biological technologies such as high-throughput sequencing, transcriptomics, and metabolomics, it appears that the microbial signature varies dynamically among individuals, creating various roles in metabolism, local and systemic inflammation, and host immunity. Urinary and genital organs, including the prostate, seminal vesicles, and urinary bladder, are reservoirs of several bacterial, viral, and fungal communities. Accumulating evidence has suggested profound roles for the gut, urinary, and intraprostate microbiomes in genitourinary benign and malignant diseases. This review article addresses microbiome-related evidence for three major diseases involved in prostate cancer: chronic prostatitis (CP), benign prostatic hyperplasia (BPH), and prostate cancer (PCa). Symptomatic CP is known as CP/chronic pelvic pain syndrome. CP is one of the most common prostate diseases in young men, accounting for 8% of all men visiting a urologic clinic. Although oral medication is the gold standard therapy for patients with BPH, approximately 13% of men present with clinical progression within 4 years after the initiation of treatment, with 5% requiring surgical intervention. The identification of proinflammatory cytokines and pathogens responsible for the clinical progression of BPH is still underway. Several topics regarding the association between PCa and the microbiome are discussed in this review as follows: i) intraprostatic microbiome and the risk of PCa, ii) gut microbiome and PCa, iii) gut microbiome and the risk of radiation-induced side effects, iv) isoflavone intake and equol-producing intestinal flora on PCa, and v) the inhibitory effect of daidzein and equol on tumor growth and progression of PCa. Further studies are required for a comprehensive understanding between the urogenital microbiome and prostate pathogenesis to facilitate the development of preventive and therapeutic approaches for prostate diseases.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 2","pages":"Pages 96-107"},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888222000174/pdfft?md5=428e4d0fd6434515df8f9948d6c641b0&pid=1-s2.0-S2287888222000174-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45334601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial experience of single-port robot-assisted radical prostatectomy: A single surgeon's experience with technique description","authors":"Tae Il Noh,&nbsp;Jong Hyun Tae,&nbsp;Ji Sung Shim,&nbsp;Seok Ho Kang,&nbsp;Jun Cheon,&nbsp;Jeong Gu Lee,&nbsp;Sung Gu Kang","doi":"10.1016/j.prnil.2021.10.003","DOIUrl":"10.1016/j.prnil.2021.10.003","url":null,"abstract":"<div><h3>Background</h3><p>With the implementation of da Vinci SP robot platform (Intuitive Surgical, Inc., Sunnyvale, CA, USA), we described our initial experience with the da Vinci SP robot platform (Intuitive Surgical, Inc., Sunnyvale, CA, USA) for single-port robotic-assisted radical prostatectomy (SP-RARP).</p></div><div><h3>Methods</h3><p>This retrospective review included 30 consecutive patients with prostate biopsy-confirmed prostate cancer who underwent SP-RARP by a single surgeon between June and November 2020. SP-RARP was performed with a single-incision plus one method, in which the multichannel guide port was inserted directly with an additional assist port. We report our initial experience of perioperative and early functional outcomes.</p></div><div><h3>Results</h3><p>The mean operative time (SD), console time (SD), and blood loss were 142.8 (15.1) min, 109.9 (15.7) min, and 133.0 (72.9) mL, respectively. No intraoperative complications or blood transfusions were reported. Of the 30 patients, 21 (70.0%), 7 (23.3%) and 2 (6.7%) had stage pT2, pT3a and pT3b disease, respectively. Positive surgical margins were reported in 5 of the 30 (16.7%) patients in the final pathology report, including 2 of 21 (9.5%) with stage pT2 and 3 of 9 (33.3%) with ≥ pT3. At 12 weeks after SP-RARP, 80.0% of patients had achieved continence and the potency was 46.7%; 8 of 11 (72.7%) had sexual health inventory for men (SHIM) scores ≥ 17 and 6 of 19 (31.6%) had SHIM scores &lt; 17.</p></div><div><h3>Conclusions</h3><p>The SP platform for radical prostatectomy was technically safe and feasible. After overcoming the technical learning curve, this platform may provide high-quality outcomes comparable to those of multi-port platforms.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 2","pages":"Pages 85-91"},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888221000581/pdfft?md5=d611436f8e9ec72b70346ba5278bb2eb&pid=1-s2.0-S2287888221000581-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44690214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer","authors":"Yuping Zeng ,&nbsp;Xiaoming Leng ,&nbsp;Hengbin Liao ,&nbsp;Guihua Jiang ,&nbsp;Ping Chen","doi":"10.1016/j.prnil.2022.03.003","DOIUrl":"10.1016/j.prnil.2022.03.003","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the diagnostic value of fluorine 18 (¹⁸F)-labeled prostate-specific membrane antigen (PSMA)-1007 Positron emission tomography/Magnetic resonance imaging (PET/MRI) and compared with that of biparametric MRI (bpMRI) for the detection of prostate cancer (PCa).</p></div><div><h3>Materials and methods</h3><p>The study enrolled 29 patients with suspected PCa preoperatively who underwent ¹⁸F-PSMA-1007 PET/MRI and subsequent targeted biopsy for suspected PCa lesions. Two readers independently assessed the images of each suspected PCa lesion and determined their overall assessment category on bpMRI and ¹⁸F-PSMA-1007 PET/MRI. By using biopsy histopathology as the reference standard, the accuracies of ¹⁸F-PSMA-1007 PET/MRI and bpMRI for the detection of PCa lesion were determined. Furthermore, the receiver-operating characteristic (ROC) curves of their semi-quantitative parameters of the optimal standardized uptake value (SUVmax) and apparent diffusion coefficient (ADC) for detecting PCa lesions were derived, and their correlations with the International Society of Urological Pathology (ISUP) grade were reported.</p></div><div><h3>Results</h3><p>Of the 48 suspected PCa lesions in 29 patients, 38 were pathologically diagnosed with clinically significant PCa and 10 with nonprostate cancer (non-PCa) lesions. Compared with the pathological results, ¹⁸F-PSMA-1007 PET/MRI demonstrated much greater diagnostic accuracy (area under the curve, AUC), sensitivity, specificity, positive predictive value, and negative predictive value than bpMRI: 0.974 versus 0.711, 94.74% versus 92.11%, 100% versus 50%, 100% versus 87.50%, and 83.33% versus 62.50%, respectively. The semi-quantitative parameters of SUVmax demonstrated a higher AUC of 0.874 than that of ADC with 0.776 for detecting PCa. The ISUP grade was positively associated with SUVmax at spearman’s rho correlation coefficient (Rho) = 0.539, p = 0), but not associated with ADC (Rho = −0.105, p = 0.529).</p></div><div><h3>Conclusion</h3><p>The diagnostic value of ¹⁸F-PSMA-1007 PET/MRI for the detection of PCa is better than that of bpMRI, and a high SUVmax may indicate a lesion with a high ISUP grade.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"10 2","pages":"Pages 108-116"},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888222000162/pdfft?md5=0c3988dded48189e5135f16ea1f6c926&pid=1-s2.0-S2287888222000162-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44788711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}